ATRi elicit anti‐tumour effects in both pre‐clinical cancer model systems [67] and in early phase clinical trials [68], without eliciting severe, non‐tumour toxicity; this is presumably because ATR inhibition exacerbates pre‐existing tumour cell‐specific RS to the point where tumour cells are not viable. The gene discussed is ATR; the disease is cancer.